SHP1 expression in bone marrow biopsies of myelodysplastic syndrome patients: a new prognostic factor

Br J Haematol. 2005 Jun;129(6):791-4. doi: 10.1111/j.1365-2141.2005.05516.x.

Abstract

Myelodysplastic syndrome (MDS) progresses into acute leukaemia with a variable time course. We analysed 45 newly diagnosed patients and found that the expression of the Src homology 2 domain-containing tyrosine phosphatase 1 (SHP1) had a significant impact on disease severity, progression and overall prognosis. Global or lineage-specific loss of SHP1 was observed by immunohistochemistry in bone marrow biopsies of MDS patients who progressed rapidly (P = 0.0021) and had shorter survival (P < 0.001). Cox regression analysis demonstrated that SHP1 expression in megakaryocytes had prognostic relevance for time to progression (P = 0.009) and overall survival (P = 0.001).

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers / metabolism
  • Biopsy
  • Bone Marrow / enzymology*
  • Disease Progression
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Intracellular Signaling Peptides and Proteins
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / enzymology*
  • Prognosis
  • Protein Phosphatase 1
  • Protein Tyrosine Phosphatase, Non-Receptor Type 6
  • Protein Tyrosine Phosphatases / metabolism*
  • Survival Analysis

Substances

  • Biomarkers
  • Intracellular Signaling Peptides and Proteins
  • Protein Phosphatase 1
  • PTPN6 protein, human
  • Protein Tyrosine Phosphatase, Non-Receptor Type 6
  • Protein Tyrosine Phosphatases